{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_17040", "batch_size": 260, "batch_pos": 159, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain high-potency verbs, potent metaphors, superlative-negative nouns, or critical alert phrases describing the threat's impact.", "method": "llm_batch", "batch_id": "batch_2_8824", "batch_size": 260, "batch_pos": 151, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 3, "answer": "no", "rationale": "The moderate verb ('climbed') refers to financial metrics, which are excluded.", "method": "llm_batch", "batch_id": "batch_3_11616", "batch_size": 260, "batch_pos": 136, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_9256", "batch_size": 260, "batch_pos": 132, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 5, "answer": "no", "rationale": "The segment reports a financial/business fact, lacking explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_17708", "batch_size": 260, "batch_pos": 130, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_5816", "batch_size": 260, "batch_pos": 116, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 7, "answer": "no", "rationale": "The segment states shares climbed, which is a factual report, not a bare negation.", "method": "llm_batch", "batch_id": "batch_7_17232", "batch_size": 260, "batch_pos": 113, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 8, "answer": "yes", "rationale": "Describes potential funding for a trial ('government is near a deal to fund a late-stage trial') as a development capability without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_1736", "batch_size": 260, "batch_pos": 76, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
